Publications

Immune checkpoint blockade in desmoplastic melanoma. Mo G, Mitchell TC. Nat Cancer. 2026 Feb 6. doi: 10.1038/s43018-026-01118-1. Epub ahead of print. PMID: 41652219.

Compliance with guidelines and timeliness of sentinel lymph node biopsy for Merkel cell carcinoma treated with Mohs micrographic surgery versus conventional excision at a tertiary academic center. Trifoi MD, Morales KV, Frankel D, Lin SK, Deitermann AM, Haynes D, Lubeck M, Etzkorn JR, Sobanko JF, Giordano CN, Walker JL, Zhang J, Lewis DJ, Higgins HW 2nd, Miura JT, Karakousis GC, Rajasekaran K, Cannady SB, Brody RM, Mitchell TC, Amaravadi RK, Lukens JN, Miller CJ. J Am Acad Dermatol. 2026 Feb;94(2):688-690. doi: 10.1016/j.jaad.2025.10.053. Epub 2025 Oct 16. PMID: 41109449.

Mohs micrographic surgery of Merkel cell carcinoma lowers local recurrence risk and has similar metastasis and survival compared with conventional excision: A single-center retrospective cohort study. Lin SK, Deitermann AM, Miller CJ, Ricciardelli K, Sharma M, Haynes D, Cheng B, Daneshpajouhnejad P, Valdes-Morales K, Trifoi MD, Frankel D, Etzkorn JR, Modi M, Sobanko JF, Giordano CN, Walker JL, Zhang J, Nguyen HP, Lewis DJ, Higgins HW 2nd. J Am Acad Dermatol. 2026 Feb;94(2):675-678. doi: 10.1016/j.jaad.2025.10.046. Epub 2025 Oct 17. PMID: 41109445.

Accuracy of Sentinel Lymph Node Biopsy to Predict Nodal Metastasis in Head and Neck Merkel Cell Carcinoma. Wang SY, Turner G, Valdes-Morales KL, Hunter ER, Kim M, Tran VA, Polen K, Haynes D, Miller CJ, Etzkorn JR, Sobanko JF, Walker JL, Zhang J, Brody RM, Cannady SB, Rajasekaran K, Farwell DG, Miura JT, Karakousis GC, Lukens JR, Amaravadi RK, Schuchter LM, Mitchell TC, Higgins HW 2nd, Carey RM. JAMA Otolaryngol Head Neck Surg. 2026 Jan 29:e255211. doi: 10.1001/jamaoto.2025.5211. Epub ahead of print. PMID: 41609724; PMCID: PMC12856741.

Immune signature-based uncoupling of checkpoint inhibitor efficacy and toxicity. Lucas MW, Burton EM, Dimitriadis P, Huang AC, Long GV, Mitchell TC, Amaria RN, Blank CU. Immunity. 2026 Jan 13;59(1):29-33.e2. doi: 10.1016/j.immuni.2025.11.021. Epub 2025 Dec 31. PMID: 41478279.

Antigen-specific profiling identifies T-bet⁺ melanoma-specific CD8⁺ T cells associated with response to neoadjuvant PD-1 blockade. Wang G, Yoon D, Nandi A, Patel K, Azar T, Kim J, Han NA, Nickie A, Park S, Wang K, Yan P, Divaker S, Tabita-Martinez J, Giles L, Carberry M, Beltra JC, Painter MM, Alanio C, Amaravadi RK, Schuchter LM, Carreno BM, Linette GP, Elder DE, Brody RM, Gimotty P, Miura JT, Karakousis GC, Xu X, Mitchell TC, Huang AC. Cancer Cell. 2026 Jan 12;44(1):221-234.e5. doi: 10.1016/j.ccell.2025.12.004. Epub 2025 Dec 31. PMID: 41478278.

ASO Visual Abstract: Single-Dose Neoadjuvant Pembrolizumab in Resectable Metastatic Melanoma. Shafique N, Farooq MS, Mattfeld V, Vargas GM, Xu X, Schuchter L, Amaravadi R, Mitchell T, Miura J, Karakousis G. Ann Surg Oncol. 2025 Dec;32(13):9685-9686. doi: 10.1245/s10434-025-18507-y. PMID: 41062897.

DR5 CAR-T cells target melanoma and suppress MDSCs with minimal toxicity. Wang H, Liu S, Sinha P, Liu F, Zhang X, Guo Y, Goncalves B, Zheng Q, Mou H, Yang J, Huang L, Miao F, Zeng T, Karakousis G, Huang AC, Mitchell T, Amaravadi R, Schuchter L, Milone M, Guo W, June C, Herlyn M, Fan Y, Xu X. Mol Ther. 2025 Dec 11:S1525-0016(25)01048-2. doi: 10.1016/j.ymthe.2025.12.025. Epub ahead of print. PMID: 41383014; PMCID: PMC12790342.

Brain metastasis patient-derived xenograft models to characterize the contribution of brain microenvironment to metastatic outgrowth. Oliveira-Nunes MC, Ma W, Mao C, S Huo B, Rios Angulo A, Landa Bianchi G, Ray P, Chen Q. Neurooncol Adv. 2025 Nov 19;7(1):vdaf239. doi: 10.1093/noajnl/vdaf239. PMID: 41497454; PMCID: PMC12768502.

Taxonomy-free fecal microbiome profiles enable robust prediction of immunotherapy response and toxicity in melanoma. Lucas A, Reale M, Wolf YI, Duong B, Zhang Y, Wickramasinghe J, Behlman L, Jones SM, Higgins S, Moustafa AM, Elbasir A, Amaravadi R, Mitchell T, Huang A, Auslander N. bioRxiv [Preprint]. 2025 Nov 7:2025.11.06.686285. doi: 10.1101/2025.11.06.686285. PMID: 41279814; PMCID: PMC12637426.

Sequencing of Immunotherapy and Outcomes in Operable Clinical Stage III Melanoma: A National Cohort Study. Dheer A, Tortorello GN, Shafique N, Farooq MS, Mitchell TC, Xu X, Miura JT, Karakousis GC.J Surg Oncol. 2025 Mar;131(3):365-370. doi: 10.1002/jso.27933. Epub 2024 Oct 3. PMID: 39359153; PMCID: PMC12044280.

CRTC1::TRIM11 Cutaneous Tumor Mimicking Primary Dermal Melanoma: Case Report With Literature Review. Hirai I, Walker JL, Rubin AI, Chu EY, Elenitsas R. Am J Dermatopathol. 2025 Dec 1;47(12):971-975. doi: 10.1097/DAD.0000000000003108. Epub 2025 Aug 26. PMID: 40857736.

Mohs micrographic surgery reduces the risk of reconstruction with positive margins, repeat surgeries, and time to definitive reconstruction compared to conventional excision of hand and foot melanomas: A retrospective cohort study. Frankel D, Valdes-Morales K, Trifoi MD, Lin SK, Deitermann AM, Banala M, Zhang E, Easo N, Lubeck M, Haynes D, Lewis D, Nugent ST, Etzkorn JR, Jariwala NN, Zhang J, Walker JL, Higgins HW 2nd, Sobanko JF, Giordano CN, Daneshpajouhnejad P, Modi M, Lin IC, Chang B, Wink J, Karakousis G, Miura J, Miller CJ. J Am Acad Dermatol. 2025 Jul;93(1):157-164. doi: 10.1016/j.jaad.2025.03.012. Epub 2025 Mar 11. PMID: 40081664.

Nail unit melanoma treated with Mohs micrographic surgery: Technique, local recurrence rate, and surgical outcomes. Valdes Morales KL, Frankel D, Trifoi MD, Lin SK, Deitermann AM, Lubeck M, Sobanko JF, Higgins HW 2nd, Giordano CN, Walker JL, Zhang J, Lewis DJ, Chang B, Wink JD, Lin IC, Kovach SJ 3rd, Etzkorn JR, Miller CJ. J Am Acad Dermatol. 2025 May;92(5):1072-1079. doi: 10.1016/j.jaad.2024.11.078. Epub 2025 Jan 21. PMID: 39848587.

Outcomes of Immunotherapy Treatment in Sinonasal Mucosal Melanoma. Kshirsagar RS, Eide JG, Harris J, Abiri A, Beswick DM, Chang EH, Fung N, Hong M, Johnson BJ, Kohanski MA, Le CH, Lee JT, Nabavizadeh SA, Obermeyer IP, Pandrangi VC, Pinheiro-Neto CD, Smith TL, Snyderman CH, Suh JD, Wang EW, Wang MB, Choby G, Geltzeiler M, Lazor J, Mitchell TC, Kuan EC, Palmer JN, Adappa ND. Am J Rhinol Allergy. 2025 Mar;39(2):102-108. doi: 10.1177/19458924241308953. Epub 2025 Jan 9. PMID: 39782303.

Divergent effects of acute and chronic PPT1 inhibition in melanoma. Crissey MAS, Versace A, Bhardwaj M, Jain V, Liu S, Singh A, Beer LA, Tang HY, Villanueva J, Gimotty PA, Xu X, Amaravadi RK. Autophagy. 2025 Feb;21(2):394-406. doi: 10.1080/15548627.2024.2403152. Epub 2024 Sep 19. PMID: 39265628; PMCID: PMC11760279.

Selective abrogation of S6K2 identifies lipid homeostasis as a survival vulnerability in MAPK inhibitor-resistant NRAS-mutant melanoma. Lipchick B, Guterres AN, Chen HY, Zundell DM, Del Aguila S, Reyes-Uribe PI, Tirado Y, Basu S, Yin X, Kossenkov AV, Lu Y, Mills GB, Liu Q, Goldman AR, Murphy ME, Speicher DW, Villanueva J. Sci Transl Med. 2025 Feb 5;17(784):eadp8913. doi: 10.1126/scitranslmed.adp8913. Epub 2025 Feb 5. PMID: 39908352.

Engineered extracellular vesicles with DR5 agonistic scFvs simultaneously target tumor and immunosuppressive stromal cells. Guo Y, Wang H, Liu S, Zhang X, Zhu X, Huang L, Zhong W, Guan L, Chen Y, Xiao M, Ou L, Yang J, Chen X, Huang AC, Mitchell T, Amaravadi R, Karakousis G, Miura J, Schuchter L, Flowers A, Zheng Q, Mou H, Gimotty P, Herlyn M, Guo W, Xu X. Sci Adv. 2025 Jan 17;11(3):eadp9009. doi: 10.1126/sciadv.adp9009. Epub 2025 Jan 15. PMID: 39813334; PMCID: PMC11734719.

Tumor-infiltrating lymphocytes in necrotic tumors after melanoma neoadjuvant anti-PD1 therapy correlate with pathological response and recurrence-free survival. Ma KL, Mitchell TC, Dougher M, Sharon CE, Tortorello GN, Elder DE, Morgan EE, Gimotty PA, Huang AC, Amaravadi RK, Schuchter LM, Flowers A, Miura JT, Karakousis GC, Xu X. Clin Cancer Res. 2024 Sep 9. doi: 10.1158/1078-0432.CCR-23-3775. Epub ahead of print. PMID: 39248505.

Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8⁺ T cells. Wang K, Coutifaris P, Brocks D, Wang G, Azar T, Solis S, Nandi A, Anderson S, Han N, Manne S, Kiner E, Sachar C, Lucas M, George S, Yan PK, Kier MW, Laughlin AI, Kothari S, Giles J, Mathew D, Ghinnagow R, Alanio C, Flowers A, Xu W, Tenney DJ, Xu X, Amaravadi RK, Karakousis GC, Schuchter LM, Buggert M, Oldridge D, Minn AJ, Blank C, Weber JS, Mitchell TC, Farwell MD, Herati RS, Huang AC. Cancer Cell. 2024 Aug 26:S1535-6108(24)00306-4. doi: 10.1016/j.ccell.2024.08.007. Epub ahead of print. PMID: 39214097.

LAG-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity. Ngiow SF, Manne S, Huang YJ, Azar T, Chen Z, Mathew D, Chen Q, Khan O, Wu JE, Alcalde V, Flowers AJ, McClain S, Baxter AE, Kurachi M, Shi J, Huang AC, Giles JR, Sharpe AH, Vignali DAA, Wherry EJ. Cell. 2024 Aug 8;187(16):4336-4354.e19. doi: 10.1016/j.cell.2024.07.018. PMID: 39121847.

Valuable insights from the epacadostat plus pembrolizumab clinical trials in solid cancers. Mitchell TC. BMC Cancer. 2024 Jul 25;23(Suppl 1):1269. doi: 10.1186/s12885-024-12432-1. PMID: 39054487; PMCID: PMC11270756.

Anti-TRPM1 autoantibody-positive unilateral melanoma associated retinopathy (MAR) triggered by immunotherapy recapitulates functional and structural details of TRPM1-associated congenital stationary night blindness. Cohen DC, Sumaroka A, Paulos JA, Mitchell TC, Santos AJ, O'Neil EC, Bedoukian EC, Adamus G, Cideciyan AV, Aleman TS.  Am J Ophthalmol Case Rep. 2024 Jul 5;36:102098. doi: 10.1016/j.ajoc.2024.102098. PMID: 39109318; PMCID: PMC11301341.

FDG PET/CT imaging 1 week after a single dose of pembrolizumab predicts treatment response in patients with advanced melanoma. Anderson TM, Chang BH, Huang AC, Xu X, Yoon D, Shang CG, Mick R, Schubert E, McGettigan S, Kreider K, Xu W, Wherry EJ, Schuchter LM, Amaravadi RK, Mitchell TC, Farwell MD. Clin Cancer Res. 2024 Jan 24.

Upregulation of exosome secretion from tumor-associated macrophages plays a key role in the suppression of anti-tumor immunity. Zhong W, Lu Y, Han X, Yang J, Qin Z, Zhang W, Yu Z, Wu B, Liu S, Xu W, Zheng C, Schuchter LM, Karakousis GC, Mitchell TC, Amaravadi R, Flowers AJ, Gimotty PA, Xiao M, Mills G, Herlyn M, Dong H, Mitchell MJ, Kim J, Xu X, Guo W. Cell Rep. 2023 Oct 31.

Impact of Adjuvant Immunotherapy on Overall Survival in a Contemporary Cohort of Patients with Stage III Melanoma. Sharon CE, Tortorello GN, Ma K, Sinnamon AJ, Mitchell TC, Karakousis GC, Miura JT. Ann Surg Oncol. 2023 Sep;30(9):5329-5332. doi: 10.1245/s10434-023-13736-5. Epub 2023 Jun 19. PMID: 37332026; PMCID: PMC11218604.

Patient-derived melanoma organoid models facilitate the assessment of immunotherapies. Ou L, Liu S, Wang H, Guo Y, Guan L, Shen L, Luo R, Elder DE, Huang AC, Karakousis G, Miura J, Mitchell T, Schuchter L, Amaravadi R, Flowers A, Mou H, Yi F, Guo W, Ko J, Chen Q, Tian B, Herlyn M, Xu X. EBioMedicine. 2023 Jun.

Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma. Shah PD, Huang AC, Xu X, Orlowski R, Amaravadi RK, Schuchter LM, Zhang P, Tchou J, Matlawski T, Cervini A, Shea J, Gilmore J, Lledo L, Dengel K, Marshall A, Wherry EJ, Linette GP, Brennan A, Gonzalez V, Kulikovskaya I, Lacey SF, Plesa G, June CH, Vonderheide RH, Mitchell TC. Cancer Res Commun. 2023 May 9;3(5):821-829. doi: 10.1158/2767-9764.CRC-22-0486. PMID: 37377890; PMCID: PMC10167933.

Sentinel lymph node biopsy status improves adjuvant therapy decision-making in patients with clinical stage IIB/C melanoma: A population-based analysis. Sharon CE, Straker RJ 3rd, Gimotty PA, Chu EY, Mitchell TC, Miura JT, Marchetti MA, Bartlett EK, Karakousis GC. J Am Acad Dermatol. 2023 Apr.

Autophagy Paradox: Strategizing Treatment Modality in Melanoma. Pangilinan C, Xu X, Herlyn M, Liang C. Curr Treat Options Oncol. 2023 Feb;24(2):130-145. doi: 10.1007/s11864-023-01053-8. Epub 2023 Jan 21. PMID: 36670319; PMCID: PMC9883356.

Shared and distinct biological circuits in effector, memory and exhausted CD8⁺ T cells revealed by temporal single-cell transcriptomics and epigenetics. Giles JR, Ngiow SF, Manne S, Baxter AE, Khan O, Wang P, Staupe R, Abdel-Hakeem MS, Huang H, Mathew D, Painter MM, Wu JE, Huang YJ, Goel RR, Yan PK, Karakousis GC, Xu X, Mitchell TC, Huang AC, Wherry EJ. Nat Immunol. 2022 Nov;23(11):1600-1613. doi: 10.1038/s41590-022-01338-4. Epub 2022 Oct 21. PMID: 36271148; PMCID: PMC10408358.

Personalizing the approach to neoadjuvant therapy: a promising path to improving outcomes of resectable melanoma. Karakousis GC, Mitchell TC. Nat Rev Clin Oncol. 2022 Nov;19(11):679-680. doi: 10.1038/s41571-022-00677-3. PMID: 36042382.

Peroxynitrite in the tumor microenvironment changes the profile of antigens allowing escape from cancer immunotherapy. Tcyganov EN, Sanseviero E, Marvel D, Beer T, Tang HY, Hembach P, Speicher DW, Zhang Q, Donthireddy LR, Mostafa A, Tsyganova S, Pisarev V, Laufer T, Ignatov D, Ferrone S, Meyer C, Maby-El Hajjami H, Speiser DE, Altiok S, Antonia S, Xu X, Xu W, Zheng C, Schuchter LM, Amaravadi RK, Mitchell TC, Karakousis GC, Yuan Z, Montaner LJ, Celis E, Gabrilovich DI. Cancer Cell. 2022 Oct 10.

Moderate Colitis Not Requiring Intravenous Steroids Is Associated with Improved Survival in Stage IV Melanoma after Anti-CTLA4 Monotherapy, But Not Combination Therapy. Anstadt EJ, Chu B, Yegya-Raman N, Han X, Doucette A, Poirier K, Mohiuddin JJ, Maity A, Facciabene A, Amaravadi RK, Karakousis GC, Cohen JV, Mitchell TC, Schuchter LM, Lukens JN. Oncologist. 2022 Sep 2;27(9):799-808. doi: 10.1093/oncolo/oyac108. PMID: 35666292; PMCID: PMC9438915.

PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine. Herati RS, Knorr DA, Vella LA, Silva LV, Chilukuri L, Apostolidis SA, Huang AC, Muselman A, Manne S, Kuthuru O, Staupe RP, Adamski SA, Kannan S, Kurupati RK, Ertl HCJ, Wong JL, Bournazos S, McGettigan S, Schuchter LM, Kotecha RR, Funt SA, Voss MH, Motzer RJ, Lee CH, Bajorin DF, Mitchell TC, Ravetch JV, Wherry EJ. Nat Immunol. 2022 Aug;23(8):1183-1192. doi: 10.1038/s41590-022-01274-3. Epub 2022 Jul 28. PMID: 35902637; PMCID: PMC9880663.

Preclinical platforms to study therapeutic efficacy of human γδ T cells. Ou L, Wang H, Huang H, Zhou Z, Lin Q, Guo Y, Mitchell T, Huang AC, Karakousis G, Schuchter L, Amaravadi R, Guo W, Salvino J, Herlyn M, Xu X. Clin Transl Med. 2022 Jun;12(6):e814. doi: 10.1002/ctm2.814. PMID: 35731974; PMCID: PMC9217106.

Stromal changes in the aged lung induce an emergence from melanoma dormancy. Fane ME, Chhabra Y, Alicea GM, Maranto DA, Douglass SM, Webster MR, Rebecca VW, Marino GE, Almeida F, Ecker BL, Zabransky DJ, Hüser L, Beer T, Tang HY, Kossenkov A, Herlyn M, Speicher DW, Xu W, Xu X, Jaffee EM, Aguirre-Ghiso JA, Weeraratna AT. Nature. 2022 Jun;606(7913):396-405. doi: 10.1038/s41586-022-04774-2. Epub 2022 Jun 1. Erratum in: Nature. 2025 Feb;638(8051):E31. doi: 10.1038/s41586-025-08659-y. PMID: 35650435; PMCID: PMC9554951.

BAMM (BRAF autophagy and MEK inhibition in melanoma): A phase I/II trial of dabrafenib, trametinib, and hydroxychloroquine in advanced BRAFV600-mutant melanoma. Mehnert JM, Mitchell TC, Huang AC, Aleman TS, Kim BJ, Schuchter LM, Linette GP, Karakousis GC, Mitnick S, Giles L, Carberry M, Frey N, Kossenkov A, Groisberg R, Hernandez-Aya LF, Ansstas G, Silk AW, Chandra S, Sosman JA, Gimotty PA, Mick R, Amaravadi RK. Clin Cancer Res. 2022 Mar 15.

Human epigenetic and transcriptional T cell differentiation atlas for identifying functional T cell-specific enhancers. Giles JR, Manne S, Freilich E, Oldridge DA, Baxter AE, George S, Chen Z, Huang H, Chilukuri L, Carberry M, Giles L, Weng NP, Young RM, June CH, Schuchter LM, Amaravadi RK, Xu X, Karakousis GC, Mitchell TC, Huang AC, Shi J, Wherry EJ. Immunity. 2022 Mar 8;55(3):557-574.e7. doi: 10.1016/j.immuni.2022.02.004. PMID: 35263570; PMCID: PMC9214622.

ICAM-1-mediated adhesion is a prerequisite for exosome-induced T cell suppression. Zhang W, Zhong W, Wang B, Yang J, Yang J, Yu Z, Qin Z, Shi A, Xu W, Zheng C, Schuchter LM, Karakousis GC, Mitchell TC, Amaravadi R, Herlyn M, Dong H, Gimotty PA, Daaboul G, Xu X, Guo W. Dev Cell. 2022 Feb 7.

Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance. Liu J, Rebecca VW, Kossenkov AV, Connelly T, Liu Q, Gutierrez A, Xiao M, Li L, Zhang G, Samarkina A, Zayasbazan D, Zhang J, Cheng C, Wei Z, Alicea GM, Fukunaga-Kalabis M, Krepler C, Aza-Blanc P, Yang CC, Delvadia B, Tong C, Huang Y, Delvadia M, Morias AS, Sproesser K, Brafford P, Wang JX, Beqiri M, Somasundaram R, Vultur A, Hristova DM, Wu LW, Lu Y, Mills GB, Xu W, Karakousis GC, Xu X, Schuchter LM, Mitchell TC, Amaravadi RK, Kwong LN, Frederick DT, Boland GM, Salvino JM, Speicher DW, Flaherty KT, Ronai ZA, Herlyn M. Cancer Res. 2021 Oct 15;81(20):5230-5241. doi: 10.1158/0008-5472.CAN-20-1496. Epub 2021 Aug 30. PMID: 34462276; PMCID: PMC8530965.

Complete Response After Stereotactic Body Radiation Therapy With Concurrent Immunotherapy for Vaginal Melanoma. Schonewolf CA, Jaworski EM, Allen SG, McLean K, Lao CD, Schuchter LM, Tanyi J, Taunk NK. Adv Radiat Oncol. 2021 Oct 28;7(2):100839. doi: 10.1016/j.adro.2021.100839. PMID: 34934869; PMCID: PMC8654617.

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma. Wang B, Zhang W, Zhang G, Kwong L, Lu H, Tan J, Sadek N, Xiao M, Zhang J, Labrie M, Randell S, Beroard A, Sugarman E, Rebecca VW, Wei Z, Lu Y, Mills GB, Field J, Villanueva J, Xu X, Herlyn M, Guo W. Oncogene. 2021 Sep.

Role of nuclear localization in the regulation and function of T-bet and Eomes in exhausted CD8 T cells. McLane LM, Ngiow SF, Chen Z, Attanasio J, Manne S, Ruthel G, Wu JE, Staupe RP, Xu W, Amaravadi RK, Xu X, Karakousis GC, Mitchell TC, Schuchter LM, Huang AC, Freedman BD, Betts MR, Wherry EJ. Cell Rep. 2021 May 11;35(6):109120. doi: 10.1016/j.celrep.2021.109120. PMID: 33979613; PMCID: PMC8195461.

Dichotomous and stable gamma delta T-cell number and function in healthy individuals. Ou L, Wang H, Liu Q, Zhang J, Lu H, Luo L, Shi C, Lin S, Dong L, Guo Y, Huang L, Zhu J, Yin X, Huang AC, Karakousis G, Schuchter L, Amaravadi R, Zheng C, Fan Y, Guo W, Xu X. J Immunother Cancer. 2021 May;9(5):e002274. doi: 10.1136/jitc-2020-002274. PMID: 34011536; PMCID: PMC8137237.

Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. Robert C, Hwu WJ, Hamid O, Ribas A, Weber JS, Daud AI, Hodi FS, Wolchok JD, Mitchell TC, Hersey P, Dronca R, Joseph RW, Boutros C, Min L, Long GV, Schachter J, Puzanov I, Dummer R, Lin J, Ibrahim N, Diede SJ, Carlino MS, Joshua AM. Eur J Cancer. 2021 Feb;144:182-191. doi: 10.1016/j.ejca.2020.11.010. Epub 2020 Dec 24. PMID: 33360855; PMCID: PMC8388128.

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Menzies AM, Amaria RN, Rozeman EA, Huang AC, Tetzlaff MT, van de Wiel BA, Lo S, Tarhini AA, Burton EM, Pennington TE, Saw RPM, Xu X, Karakousis GC, Ascierto PA, Spillane AJ, van Akkooi ACJ, Davies MA, Mitchell TC, Tawbi HA, Scolyer RA, Wargo JA, Blank CU, Long GV.Nat Med. 2021 Feb;27(2):301-309. doi: 10.1038/s41591-020-01188-3. Epub 2021 Feb 8. PMID: 33558722.

Targeting regulatory T cells for immunotherapy in melanoma. Huang L, Guo Y, Liu S, Wang H, Zhu J, Ou L, Xu X. Mol Biomed. 2021;2(1):11. doi: 10.1186/s43556-021-00038-z. Epub 2021 Apr 19. PMID: 34806028; PMCID: PMC8591697.

Association of Antibiotic Exposure With Survival and Toxicity in Patients With Melanoma Receiving Immunotherapy. Mohiuddin JJ, Chu B, Facciabene A, Poirier K, Wang X, Doucette A, Zheng C, Xu W, Anstadt EJ, Amaravadi RK, Karakousis GC, Mitchell TC, Huang AC, Shabason JE, Lin A, Swisher-McClure S, Maity A, Schuchter LM, Lukens JN. J Natl Cancer Inst. 2021 Feb 1;113(2):162-170. doi: 10.1093/jnci/djaa057. PMID: 32294209; PMCID: PMC7850522.

A stratified phase I dose escalation trial of hypofractionated radiotherapy followed by ipilimumab in metastatic melanoma: long-term follow-up and final outcomes. Maity A, Mick R, Rengan R, Mitchell TC, Amaravadi RK, Schuchter LM, Pryma DA, Patsch DM, Maity AP, Minn AJ, Vonderheide RH, Lukens JN. Oncoimmunology. 2021 Jan 31;10(1):1863631. doi: 10.1080/2162402X.2020.1863631. PMID: 33643689; PMCID: PMC7872096.

Impact of Tumor-Infiltrating Lymphocytes on Overall Survival in Merkel Cell Carcinoma. Butala AA, Jain V, Reddy VK, Sebro RA, Song Y, Karakousis G, Mitchell TC, Lukens JN, Shabason JE. Oncologist. 2021 Jan;26(1):63-69. doi: 10.1634/theoncologist.2020-0070. Epub 2020 Sep 17. PMID: 32886418; PMCID: PMC7794178.

Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy. Somasundaram R, Connelly T, Choi R, Choi H, Samarkina A, Li L, Gregorio E, Chen Y, Thakur R, Abdel-Mohsen M, Beqiri M, Kiernan M, Perego M, Wang F, Xiao M, Brafford P, Yang X, Xu X, Secreto A, Danet-Desnoyers G, Traum D, Kaestner KH, Huang AC, Hristova D, Wang J, Fukunaga-Kalabis M, Krepler C, Ping-Chen F, Zhou X, Gutierrez A, Rebecca VW, Vonteddu P, Dotiwala F, Bala S, Majumdar S, Dweep H, Wickramasinghe J, Kossenkov AV, Reyes-Arbujas J, Santiago K, Nguyen T, Griss J, Keeney F, Hayden J, Gavin BJ, Weiner D, Montaner LJ, Liu Q, Peiffer L, Becker J, Burton EM, Davies MA, Tetzlaff MT, Muthumani K, Wargo JA, Gabrilovich D, Herlyn M. Nat Commun. 2021 Jan 12;12(1):346. doi: 10.1038/s41467-020-20600-7. PMID: 33436641; PMCID: PMC7804257.

Distinct Populations of Immune-Suppressive Macrophages Differentiate from Monocytic Myeloid-Derived Suppressor Cells in Cancer. Kwak T, Wang F, Deng H, Condamine T, Kumar V, Perego M, Kossenkov A, Montaner LJ, Xu X, Xu W, Zheng C, Schuchter LM, Amaravadi RK, Mitchell TC, Karakousis GC, Mulligan C, Nam B, Masters G, Hockstein N, Bennett J, Nefedova Y, Gabrilovich DI. Cell Rep. 2020 Dec 29;33(13):108571. doi: 10.1016/j.celrep.2020.108571. PMID: 33378668; PMCID: PMC7809772.

Hypohidrosis as an immune-related adverse event of checkpoint inhibitor therapy. Kersh AE, Schuchter LM, Elenitsas R, Chu EY. Immunotherapy. 2020 Sep;12(13):951-956. doi: 10.2217/imt-2020-0002. Epub 2020 Aug 10. PMID: 32772616.

Neoadjuvant Versus Adjuvant Immune Checkpoint Blockade in the Treatment of Clinical Stage III Melanoma. Song Y, Straker RJ 3rd, Xu X, Elder DE, Gimotty PA, Huang AC, Mitchell TC, Amaravadi RK, Schuchter LM, Karakousis GC. Ann Surg Oncol. 2020 Aug;27(8):2915-2926. doi: 10.1245/s10434-019-08174-1. Epub 2020 Jan 2. PMID: 31898103.

Age and Melanocytic Lesions. Shannon AB, Song Y, Xu X, Karakousis GC. . Surg Oncol Clin N Am. 2020 Jul;29(3):369-386. doi: 10.1016/j.soc.2020.02.005. PMID: 32482314.

Developmental Relationships of Four Exhausted CD8⁺ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms. Beltra JC, Manne S, Abdel-Hakeem MS, Kurachi M, Giles JR, Chen Z, Casella V, Ngiow SF, Khan O, Huang YJ, Yan P, Nzingha K, Xu W, Amaravadi RK, Xu X, Karakousis GC, Mitchell TC, Schuchter LM, Huang AC, Wherry EJ. Immunity. 2020 May 19;52(5):825-841.e8. doi: 10.1016/j.immuni.2020.04.014. Epub 2020 May 11. PMID: 32396847; PMCID: PMC8360766.

Combining Radiation with Immunotherapy: The University of Pennsylvania Experience. Luo LY, O'Hara MH, Mitchell TC, Vonderheide RH, Wherry EJ, Minn AJ, Maity A. Semin Radiat Oncol. 2020 Apr;30(2):173-180. doi: 10.1016/j.semradonc.2019.12.007. PMID: 32381296.

Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma. Webster MR, Fane ME, Alicea GM, Basu S, Kossenkov AV, Marino GE, Douglass SM, Kaur A, Ecker BL, Gnanapradeepan K, Ndoye A, Kugel C, Valiga A, Palmer J, Liu Q, Xu X, Morris J, Yin X, Wu H, Xu W, Zheng C, Karakousis GC, Amaravadi RK, Mitchell TC, Almeida FV, Xiao M, Rebecca VW, Wang YJ, Schuchter LM, Herlyn M, Murphy ME, Weeraratna AT. . Mol Cell. 2020 Feb 6;77(3):681. doi: 10.1016/j.molcel.2020.01.005. Erratum for: Mol Cell. 2020 Feb 6;77(3):633-644.e5. doi: 10.1016/j.molcel.2019.11.009. PMID: 32032511; PMCID: PMC7441646.

Association of Age with Efficacy of Immunotherapy in Metastatic Melanoma. Jain V, Hwang WT, Venigalla S, Nead KT, Lukens JN, Mitchell TC, Shabason JE. Oncologist. 2020 Feb;25(2):e381-e385. doi: 10.1634/theoncologist.2019-0377. Epub 2019 Oct 29. PMID: 32043765; PMCID: PMC7011618.

Association of Insurance Status With Presentation, Treatment, and Survival in Melanoma in the Era of Immune Checkpoint Inhibitors. Jain V, Venigalla S, Reddy VK, Lukens JN, Mitchell TC, Shabason JE. J Immunother. 2020 Jan;43(1):8-15. doi: 10.1097/CJI.0000000000000294. PMID: 31498180.

Survival Outcomes of Patients with Clinical Stage III Melanoma in the Era of Novel Systemic Therapies. Song Y, Tieniber AD, Gimotty PA, Mitchell TC, Amaravadi RK, Schuchter LM, Fraker DL, Karakousis GC. Ann Surg Oncol. 2019 Dec;26(13):4621-4630. doi: 10.1245/s10434-019-07599-y. Epub 2019 Jul 3. PMID: 31270717; PMCID: PMC8740891.

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, Arance A, Carlino MS, Grob JJ, Kim TM, Demidov L, Robert C, Larkin J, Anderson JR, Maleski J, Jones M, Diede SJ, Mitchell TC. Lancet Oncol. 2019 Aug;20(8):1083-1097. doi: 10.1016/S1470-2045(19)30274-8. Epub 2019 Jun 17. PMID: 31221619.

Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control. Sanseviero E, O'Brien EM, Karras JR, Shabaneh TB, Aksoy BA, Xu W, Zheng C, Yin X, Xu X, Karakousis GC, Amaravadi RK, Nam B, Turk MJ, Hammerbacher J, Rubinstein MP, Schuchter LM, Mitchell TC, Liu Q, Stone EL. Cancer Immunol Res. 2019 Aug;7(8):1371-1380. doi: 10.1158/2326-6066.CIR-18-0386. Epub 2019 Jun 25. PMID: 31239316; PMCID: PMC6956982.

TOX transcriptionally and epigenetically programs CD8⁺ T cell exhaustion. Khan O, Giles JR, McDonald S, Manne S, Ngiow SF, Patel KP, Werner MT, Huang AC, Alexander KA, Wu JE, Attanasio J, Yan P, George SM, Bengsch B, Staupe RP, Donahue G, Xu W, Amaravadi RK, Xu X, Karakousis GC, Mitchell TC, Schuchter LM, Kaye J, Berger SL, Wherry EJ. Nature. 2019 Jul;571(7764):211-218. doi: 10.1038/s41586-019-1325-x. Epub 2019 Jun 17. PMID: 31207603; PMCID: PMC6713202.

ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma. Ojha R, Leli NM, Onorati A, Piao S, Verginadis II, Tameire F, Rebecca VW, Chude CI, Murugan S, Fennelly C, Noguera-Ortega E, Chu CT, Liu S, Xu X, Krepler C, Xiao M, Xu W, Wei Z, Frederick DT, Boland G, Mitchell TC, Karakousis GC, Schuchter LM, Flaherty KT, Zhang G, Herlyn M, Koumenis C, Amaravadi RK. Cancer Discov. 2019 Mar;9(3):396-415. doi: 10.1158/2159-8290.CD-18-0348. Epub 2018 Dec 18. Erratum in: Cancer Discov. 2019 Jul;9(7):981. doi: 10.1158/2159-8290.CD-19-0632. PMID: 30563872; PMCID: PMC6397701.

A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Huang AC, Orlowski RJ, Xu X, Mick R, George SM, Yan PK, Manne S, Kraya AA, Wubbenhorst B, Dorfman L, D'Andrea K, Wenz BM, Liu S, Chilukuri L, Kozlov A, Carberry M, Giles L, Kier MW, Quagliarello F, McGettigan S, Kreider K, Annamalai L, Zhao Q, Mogg R, Xu W, Blumenschein WM, Yearley JH, Linette GP, Amaravadi RK, Schuchter LM, Herati RS, Bengsch B, Nathanson KL, Farwell MD, Karakousis GC, Wherry EJ, Mitchell TC. Nat Med. 2019 Mar;25(3):454-461. doi: 10.1038/s41591-019-0357-y. Epub 2019 Feb 25. PMID: 30804515; PMCID: PMC6699626.

ALDH1 Bio-activates Nifuroxazide to Eradicate ALDH^High Melanoma-Initiating Cells. Sarvi S, Crispin R, Lu Y, Zeng L, Hurley TD, Houston DR, von Kriegsheim A, Chen CH, Mochly-Rosen D, Ranzani M, Mathers ME, Xu X, Xu W, Adams DJ, Carragher NO, Fujita M, Schuchter L, Unciti-Broceta A, Brunton VG, Patton EE. Cell Chem Biol. 2018 Dec 20;25(12):1456-1469.e6. doi: 10.1016/j.chembiol.2018.09.005. Epub 2018 Oct 4. PMID: 30293938; PMCID: PMC6309505.

A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours. Maity A, Mick R, Huang AC, George SM, Farwell MD, Lukens JN, Berman AT, Mitchell TC, Bauml J, Schuchter LM, O'Hara M, Lin LL, Demichele A, Christodouleas JP, Haas NB, Patsch DM, Hahn SM, Minn AJ, Wherry EJ, Vonderheide RH. Br J Cancer. 2018 Nov;119(10):1200-1207. doi: 10.1038/s41416-018-0281-9. Epub 2018 Oct 15. PMID: 30318516; PMCID: PMC6251028.

Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. Zhang G, Wu LW, Mender I, Barzily-Rokni M, Hammond MR, Ope O, Cheng C, Vasilopoulos T, Randell S, Sadek N, Beroard A, Xiao M, Tian T, Tan J, Saeed U, Sugarman E, Krepler C, Brafford P, Sproesser K, Murugan S, Somasundaram R, Garman B, Wubbenhorst B, Woo J, Yin X, Liu Q, Frederick DT, Miao B, Xu W, Karakousis GC, Xu X, Schuchter LM, Mitchell TC, Kwong LN, Amaravadi RK, Lu Y, Boland GM, Wei Z, Nathanson K, Herbig U, Mills GB, Flaherty KT, Herlyn M, Shay JW. Clin Cancer Res. 2018 Oct 1;24(19):4771-4784. doi: 10.1158/1078-0432.CCR-17-2773. Epub 2018 Mar 21. PMID: 29563139; PMCID: PMC6150856.

Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy. Wang LL, Patel G, Chiesa-Fuxench ZC, McGettigan S, Schuchter L, Mitchell TC, Ming ME, Chu EY. JAMA Dermatol. 2018 Sep 1;154(9):1057-1061. doi: 10.1001/jamadermatol.2018.1912. PMID: 30027278; PMCID: PMC6143042.

Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, Yu Z, Yang J, Wang B, Sun H, Xia H, Man Q, Zhong W, Antelo LF, Wu B, Xiong X, Liu X, Guan L, Li T, Liu S, Yang R, Lu Y, Dong L, McGettigan S, Somasundaram R, Radhakrishnan R, Mills G, Lu Y, Kim J, Chen YH, Dong H, Zhao Y, Karakousis GC, Mitchell TC, Schuchter LM, Herlyn M, Wherry EJ, Xu X, Guo W. Nature. 2018 Aug;560(7718):382-386. doi: 10.1038/s41586-018-0392-8. Epub 2018 Aug 8. PMID: 30089911; PMCID: PMC6095740.

Immunotherapy in melanoma. Feld E, Mitchell TC. Immunotherapy. 2018 Aug;10(11):987-998. doi: 10.2217/imt-2017-0143. PMID: 30149766.

Pembrolizumab-induced sarcoidal infusion site reaction. Smith RJ, Mitchell TC, Chu EY. J Cutan Pathol. 2018 Jun 25. doi: 10.1111/cup.13307. Epub ahead of print. PMID: 29938827.

Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. Echevarría-Vargas IM, Reyes-Uribe PI, Guterres AN, Yin X, Kossenkov AV, Liu Q, Zhang G, Krepler C, Cheng C, Wei Z, Somasundaram R, Karakousis G, Xu W, Morrissette JJ, Lu Y, Mills GB, Sullivan RJ, Benchun M, Frederick DT, Boland G, Flaherty KT, Weeraratna AT, Herlyn M, Amaravadi R, Schuchter LM, Burd CE, Aplin AE, Xu X, Villanueva J. EMBO Mol Med. 2018 May;10(5):e8446. doi: 10.15252/emmm.201708446. PMID: 29650805; PMCID: PMC5938620.

Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. Long GV, Eroglu Z, Infante J, Patel S, Daud A, Johnson DB, Gonzalez R, Kefford R, Hamid O, Schuchter L, Cebon J, Sharfman W, McWilliams R, Sznol M, Redhu S, Gasal E, Mookerjee B, Weber J, Flaherty KT. J Clin Oncol. 2018 Mar 1;36(7):667-673. doi: 10.1200/JCO.2017.74.1025. Epub 2017 Oct 9. PMID: 28991513; PMCID: PMC10466457.

Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma. Gangadhar TC, Savitch SL, Yee SS, Xu W, Huang AC, Harmon S, Lieberman DB, Soucier D, Fan R, Black TA, Morrissette JJD, Salathia N, Waters J, Zhang S, Toung J, van Hummelen P, Fan JB, Xu X, Amaravadi RK, Schuchter LM, Karakousis GC, Hwang WT, Carpenter EL. Pigment Cell Melanoma Res. 2018 Jan;31(1):73-81. doi: 10.1111/pcmr.12623. Epub 2017 Oct 23. PMID: 28786531; PMCID: PMC5742050.

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. Krepler C, Sproesser K, Brafford P, Beqiri M, Garman B, Xiao M, Shannan B, Watters A, Perego M, Zhang G, Vultur A, Yin X, Liu Q, Anastopoulos IN, Wubbenhorst B, Wilson MA, Xu W, Karakousis G, Feldman M, Xu X, Amaravadi R, Gangadhar TC, Elder DE, Haydu LE, Wargo JA, Davies MA, Lu Y, Mills GB, Frederick DT, Barzily-Rokni M, Flaherty KT, Hoon DS, Guarino M, Bennett JJ, Ryan RW, Petrelli NJ, Shields CL, Terai M, Sato T, Aplin AE, Roesch A, Darr D, Angus S, Kumar R, Halilovic E, Caponigro G, Jeay S, Wuerthner J, Walter A, Ocker M, Boxer MB, Schuchter L, Nathanson KL, Herlyn M. Cell Rep. 2017 Nov 14;21(7):1953-1967. doi: 10.1016/j.celrep.2017.10.021. PMID: 29141225; PMCID: PMC5726788.

Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. Garman B, Anastopoulos IN, Krepler C, Brafford P, Sproesser K, Jiang Y, Wubbenhorst B, Amaravadi R, Bennett J, Beqiri M, Elder D, Flaherty KT, Frederick DT, Gangadhar TC, Guarino M, Hoon D, Karakousis G, Liu Q, Mitra N, Petrelli NJ, Schuchter L, Shannan B, Shields CL, Wargo J, Wenz B, Wilson MA, Xiao M, Xu W, Xu X, Yin X, Zhang NR, Davies MA, Herlyn M, Nathanson KL. Cell Rep. 2017 Nov 14;21(7):1936-1952. doi: 10.1016/j.celrep.2017.10.052. PMID: 29141224; PMCID: PMC5709812.

PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Lu H, Liu S, Zhang G, Bin Wu, Zhu Y, Frederick DT, Hu Y, Zhong W, Randell S, Sadek N, Zhang W, Chen G, Cheng C, Zeng J, Wu LW, Zhang J, Liu X, Xu W, Krepler C, Sproesser K, Xiao M, Miao B, Liu J, Song CD, Liu JY, Karakousis GC, Schuchter LM, Lu Y, Mills G, Cong Y, Chernoff J, Guo J, Boland GM, Sullivan RJ, Wei Z, Field J, Amaravadi RK, Flaherty KT, Herlyn M, Xu X, Guo W. Nature. 2017 Oct 5;550(7674):133-136. doi: 10.1038/nature24040. Epub 2017 Sep 27. Erratum in: Nature. 2019 Jan;565(7738):E4. doi: 10.1038/s41586-018-0814-7. PMID: 28953887; PMCID: PMC5891348.

Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Somasundaram R, Zhang G, Fukunaga-Kalabis M, Perego M, Krepler C, Xu X, Wagner C, Hristova D, Zhang J, Tian T, Wei Z, Liu Q, Garg K, Griss J, Hards R, Maurer M, Hafner C, Mayerhöfer M, Karanikas G, Jalili A, Bauer-Pohl V, Weihsengruber F, Rappersberger K, Koller J, Lang R, Hudgens C, Chen G, Tetzlaff M, Wu L, Frederick DT, Scolyer RA, Long GV, Damle M, Ellingsworth C, Grinman L, Choi H, Gavin BJ, Dunagin M, Raj A, Scholler N, Gross L, Beqiri M, Bennett K, Watson I, Schaider H, Davies MA, Wargo J, Czerniecki BJ, Schuchter L, Herlyn D, Flaherty K, Herlyn M, Wagner SN. Nat Commun. 2017 Sep 19;8(1):607. doi: 10.1038/s41467-017-00452-4. PMID: 28928360; PMCID: PMC5605714.

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, Xu W, Harmon S, Giles JR, Wenz B, Adamow M, Kuk D, Panageas KS, Carrera C, Wong P, Quagliarello F, Wubbenhorst B, D'Andrea K, Pauken KE, Herati RS, Staupe RP, Schenkel JM, McGettigan S, Kothari S, George SM, Vonderheide RH, Amaravadi RK, Karakousis GC, Schuchter LM, Xu X, Nathanson KL, Wolchok JD, Gangadhar TC, Wherry EJ. Nature. 2017 May 4;545(7652):60-65. doi: 10.1038/nature22079. Epub 2017 Apr 10. PMID: 28397821; PMCID: PMC5554367.

Acute visual loss after ipilimumab treatment for metastatic melanoma. Wilson MA, Guld K, Galetta S, Walsh RD, Kharlip J, Tamhankar M, McGettigan S, Schuchter LM, Fecher LA. J Immunother Cancer. 2016 Oct 18;4:66. doi: 10.1186/s40425-016-0170-9. PMID: 27777775; PMCID: PMC5067900.

The state of melanoma: challenges and opportunities. Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA. Pigment Cell Melanoma Res. 2016 Jul;29(4):404-16. doi: 10.1111/pcmr.12475. Epub 2016 Apr 17. PMID: 27087480; PMCID: PMC5228487.

Oncogenic BRAF-Mediated Melanoma Cell Invasion. Lu H, Liu S, Zhang G, Kwong LN, Zhu Y, Miller JP, Hu Y, Zhong W, Zeng J, Wu L, Krepler C, Sproesser K, Xiao M, Xu W, Karakousis GC, Schuchter LM, Field J, Zhang PJ, Herlyn M, Xu X, Guo W. Cell Rep. 2016 May 31;15(9):2012-24. doi: 10.1016/j.celrep.2016.04.073. Epub 2016 May 19. PMID: 27210749; PMCID: PMC4889462.

Enhancing the evaluation of PI3K inhibitors through 3D melanoma models. Shannan B, Chen Q, Watters A, Perego M, Krepler C, Thombre R, Li L, Rajan G, Peterson S, Gimotty PA, Wilson M, Nathanson KL, Gangadhar TC, Schuchter LM, Weeraratna AT, Herlyn M, Vultur A. Pigment Cell Melanoma Res. 2016 May;29(3):317-28. doi: 10.1111/pcmr.12465. Epub 2016 Mar 21. PMID: 26850518; PMCID: PMC4840066.

Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. Zhang G, Frederick DT, Wu L, Wei Z, Krepler C, Srinivasan S, Chae YC, Xu X, Choi H, Dimwamwa E, Ope O, Shannan B, Basu D, Zhang D, Guha M, Xiao M, Randell S, Sproesser K, Xu W, Liu J, Karakousis GC, Schuchter LM, Gangadhar TC, Amaravadi RK, Gu M, Xu C, Ghosh A, Xu W, Tian T, Zhang J, Zha S, Liu Q, Brafford P, Weeraratna A, Davies MA, Wargo JA, Avadhani NG, Lu Y, Mills GB, Altieri DC, Flaherty KT, Herlyn M. . J Clin Invest. 2016 May 2;126(5):1834-56. doi: 10.1172/JCI82661. Epub 2016 Apr 4. PMID: 27043285; PMCID: PMC4855947.

HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors. Budina-Kolomets A, Webster MR, Leu JI, Jennis M, Krepler C, Guerrini A, Kossenkov AV, Xu W, Karakousis G, Schuchter L, Amaravadi RK, Wu H, Yin X, Liu Q, Lu Y, Mills GB, Xu X, George DL, Weeraratna AT, Murphy ME. Cancer Res. 2016 May 1;76(9):2720-30. doi: 10.1158/0008-5472.CAN-15-2137. Epub 2016 Mar 16. PMID: 26984758; PMCID: PMC4939897.

Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. Krepler C, Xiao M, Sproesser K, Brafford PA, Shannan B, Beqiri M, Liu Q, Xu W, Garman B, Nathanson KL, Xu X, Karakousis GC, Mills GB, Lu Y, Ahmed TA, Poulikakos PI, Caponigro G, Boehm M, Peters M, Schuchter LM, Weeraratna AT, Herlyn M. Clin Cancer Res. 2016 Apr 1;22(7):1592-602. doi: 10.1158/1078-0432.CCR-15-1762. Epub 2015 Dec 16. PMID: 26673799; PMCID: PMC4818716.

Identification of Patients with Intermediate Thickness Melanoma at Low Risk for Sentinel Lymph Node Positivity. Bartlett EK, Peters MG, Blair A, Etherington MS, Elder DE, Xu XG, Guerry D, Ming ME, Fraker DL, Czerniecki BJ, Gimotty PA, Karakousis GC. Ann Surg Oncol. 2016 Jan;23(1):250-6. doi: 10.1245/s10434-015-4766-y. Epub 2015 Jul 28. PMID: 26215202; PMCID: PMC4697873.

Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma. Xu MJ, Dorsey JF, Amaravadi R, Karakousis G, Simone CB 2nd, Xu X, Xu W, Carpenter EL, Schuchter L, Kao GD. Oncologist. 2016 Jan;21(1):84-94. doi: 10.1634/theoncologist.2015-0207. Epub 2015 Nov 27. PMID: 26614709; PMCID: PMC4709205.

Miscoding of Melanoma Thickness in SEER: Research and Clinical Implications. Gimotty PA, Shore R, Lozon NL, Whitlock J, He S, Vigneau FD, Dickie L, Elder DE, Xu X, Schwartz AG, Guerry D. J Invest Dermatol. 2016 Nov;136(11):2168-2172. doi: 10.1016/j.jid.2016.05.121. Epub 2016 Jun 25. PMID: 27354265; PMCID: PMC5077675.

Chemotherapy for Melanoma. Wilson MA, Schuchter LM. Cancer Treat Res. 2016;167:209-29. doi: 10.1007/978-3-319-22539-5_8. PMID: 26601864.

Improving the Safety of Oral Chemotherapy at an Academic Medical Center. J Oncol Pract. Shah NN, Casella E, Capozzi D, McGettigan S, Gangadhar TC, Schuchter L, Myers JS.2016 Jan;12(1):e71-6. doi: 10.1200/JOP.2015.007260. Epub 2016 Jan 5. PMID: 26733627; PMCID: PMC4960462.

Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors. Amaravadi RK, Hamilton KE, Ma X, Piao S, Portillo AD, Nathanson KL, Carlino MS, Long GV, Puzanov I, Xu X, Morrissette JJ, Tsai KY, Flaherty KT, Sosman JA, Goodman GR, McArthur GA, Rustgi AK, Metz DC, Schuchter LM, Chapman PB, Sepulveda AR. Clin Cancer Res. 2015 Dec 1;21(23):5215-21. doi: 10.1158/1078-0432.CCR-15-0469. Epub 2015 Jul 22. PMID: 26202952; PMCID: PMC4668213.

miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment. Liu S, Tetzlaff MT, Wang T, Yang R, Xie L, Zhang G, Krepler C, Xiao M, Beqiri M, Xu W, Karakousis G, Schuchter L, Amaravadi RK, Xu W, Wei Z, Herlyn M, Yao Y, Zhang L, Wang Y, Zhang L, Xu X. Pigment Cell Melanoma Res. 2015 Jul;28(4):431-41. doi: 10.1111/pcmr.12379. Epub 2015 May 16. PMID: 25903073; PMCID: PMC4597606.

Broad Applicability of Nivolumab in Melanoma Regardless of BRAF Mutation Status. Gangadhar TC, Schuchter LM. JAMA Oncol. 2015 Jul;1(4):427-8. doi: 10.1001/jamaoncol.2015.1237. PMID: 26181246.

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, Amaravadi RK, Schuchter LM, Ishwaran H, Mick R, Pryma DA, Xu X, Feldman MD, Gangadhar TC, Hahn SM, Wherry EJ, Vonderheide RH, Minn AJ. Nature. 2015 Apr 16;520(7547):373-7. doi: 10.1038/nature14292. Epub 2015 Mar 9. PMID: 25754329; PMCID: PMC4401634.

BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. Wang T, Xiao M, Ge Y, Krepler C, Belser E, Lopez-Coral A, Xu X, Zhang G, Azuma R, Liu Q, Liu R, Li L, Amaravadi RK, Xu W, Karakousis G, Gangadhar TC, Schuchter LM, Lieu M, Khare S, Halloran MB, Herlyn M, Kaufman RE. Clin Cancer Res. 2015 Apr 1;21(7):1652-64. doi: 10.1158/1078-0432.CCR-14-1554. Epub 2015 Jan 23. PMID: 25617424; PMCID: PMC4383683.

Identification of secreted proteins that reflect autophagy dynamics within tumor cells. Kraya AA, Piao S, Xu X, Zhang G, Herlyn M, Gimotty P, Levine B, Amaravadi RK, Speicher DW. Autophagy. 2015;11(1):60-74. doi: 10.4161/15548627.2014.984273. PMID: 25484078; PMCID: PMC4502670.

A novel approach for the detection and genetic analysis of live melanoma circulating tumor cells. Xu MJ, Cooke M, Steinmetz D, Karakousis G, Saxena D, Bartlett E, Xu X, Hahn SM, Dorsey JF, Kao GD. PLoS One. 2015 Mar 25;10(3):e0123376. doi: 10.1371/journal.pone.0123376. PMID: 25807549; PMCID: PMC4373770.